GLP-1 Industry News: 2025–2026

The triple agonist's remaining pivotal arms reported — up to 20.8% weight loss with a 1.6-point A1C drop in type 2 diabetes, and 22.6% in established cardiovascular disease — completing the core registrational set.

The first Medicare obesity-medication coverage went live in mid-2026 — Zepbound at roughly a $50 monthly copay for qualifying beneficiaries, flowing from the 2025 manufacturer pricing deals.

The agency's running count of adverse-event reports associated with compounded tirzepatide passed 730 as of May 31, 2026 — a number that needs both its caveats and its lesson.

Lilly's triple agonist delivered the largest pharmacological weight-loss result ever recorded — up to roughly 30.3% at 80 weeks in 2,339 adults — with an 11.3% high-dose discontinuation rate as the asterisk.

The April 2026 proposed rule would formally exclude semaglutide, tirzepatide, and liraglutide from outsourcing-facility bulk compounding — closing, if finalized, the last large-scale lane.

Fifty days after filing, the FDA approved Lilly's small-molecule GLP-1 pill — any time of day, no food or water rules — launching via LillyDirect at $149/month self-pay, $25 with savings cards, ~$50 Medicare from July.

2026 analyses found the overwhelming majority of compounded GLP-1 weight-loss preparations spiked with B12 or amino acids — and identified a tirzepatide-B12 reaction product that exists in no approved drug.

In March 2026 Lilly extended its $299–$449 self-pay tiers to KwikPens at retail counters including Walmart, ending mail-order's monopoly on the cheap brand price.

Under a DOJ referral and the February enforcement climate, the biggest name in telehealth weight loss stopped compounded GLP-1 sign-ups in March 2026 — the clearest signal yet of where the market is heading.

In one coordinated action, the FDA sent roughly thirty warning letters over compounded GLP-1 marketing — approval-implying claims, equivalence language, and safety-claim overreach — resetting how the industry talks.

The administration-branded pharmacy channel launched in February 2026 listing Zepbound and Wegovy near $350 — a second door to manufacturer-tier pricing born from the 2025 pricing deals.

The Wegovy tablet arrived in early 2026 with roughly injectable-class efficacy, strict empty-stomach rules, and a $149/month introductory price that briefly undercut most of the compounded market.

Novo's amylin-plus-semaglutide combination posted 22.7% average loss at 68 weeks in late 2025 — short of sky-high expectations, ahead of everything except tirzepatide's ceiling, and headed for filing.

Under political pressure and pipeline competition, Lilly and Novo reset U.S. self-pay pricing in late 2025 — Zepbound vials $299–$449 via LillyDirect, Wegovy a flat $349 — collapsing the gap compounding was built on.

Lilly's small-molecule daily GLP-1 reported ATTAIN-1 results in 2025 — about 12.4% average weight loss with none of oral semaglutide's fasting ritual — and headed to the FDA with mass-manufacturing economics.

Tirzepatide's cardiovascular outcomes trial reported in 2025 — safety and benefit versus dulaglutide in high-risk type 2 diabetes — closing the class's last big evidence gap for the efficacy leader.

The trial everyone wanted finally reported in 2025 — 751 adults randomized to maximum-tolerated tirzepatide vs semaglutide 2.4 mg, with tirzepatide winning every weight threshold. It reset both prescribing and pricing.

March 19, 2025 was the FDA's end date for outsourcing facilities compounding tirzepatide copies; the Outsourcing Facilities Association's litigation failed to stop the clock, reshaping the market's supply base.

In February 2025 the FDA removed semaglutide from the drug-shortage list, starting the countdown that ended broad compounding: 503A pharmacies had until spring, 503B facilities weeks longer.